Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca today announced an expanded global strategic collaboration with Harbour BioMed to accelerate the discovery and development of next-generation…
AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts. The article references the simultaneous Harbour BioMed…
Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth. The release frames the AstraZeneca…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
AstraZeneca and Harbour BioMed entered a global strategic collaboration (announced March 21, 2025) with $175M in upfront/near-term payments and option fees plus up to $4.4B in development and commercial milestones, tiered royalties, and a $105M equity investment by AstraZeneca for 9.15% of newly issued Harbour BioMed shares. AstraZeneca holds an option to license preclinical programs generated on Harbour's Harbour Mice platform and nominates further targets for next-generation multi-specific antibody discovery. Harbour BioMed's H1 2025 interim results confirm AstraZeneca completed the 9.15% equity investment and the collaboration is in force. On November 23, 2025 the companies advanced the collaboration into next-generation oncology biotherapeutics, including antibody-drug conjugates (ADCs) and T cell engagers, with AstraZeneca to nominate discovery programs annually over four years; the expansion's economics are consistent with the original March 2025 framework (no new dollar figures disclosed).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Harbour BioMed (Nottingham) Ltd. (this deal) | 2025 | $4.6B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2025 deals · AstraZeneca PLC deals · Immunology deals